MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 31, 2004; DOI: 10.1124/mol.104.004135


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.004135v1
66/6/1536    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rothem, L.
Right arrow Articles by Assaraf, Y. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rothem, L.
Right arrow Articles by Assaraf, Y. G


Received for publication June 24, 2004.
Revised August 27, 2004.
Accepted for publication August 27, 2004.

Impaired CREB-1 Phosphorylation in Antifolate-Resistant Cell Lines with Down-Regulation of the Reduced Folate Carrier Gene

Lilah Rothem 1, Michal Stark 1, Yehuda G Assaraf 1*

1 The Technion-Israel Institute of Technology

* Address correspondence to: E-mail: assaraf{at}techunix.technion.ac.il

Abstract

The human reduced folate carrier (hRFC) is the dominant transporter for the uptake of antifolates used in cancer chemotherapy. Recently we have shown that decreased CRE-dependent transcription contributes to the loss of hRFC gene expression in multiple antifolate-resistant cell lines. This was associated with markedly decreased levels of phosphorylated CREB-1 (pCREB-1) and CRE-binding. Consistent with the auto-regulation of CREB-1 gene expression by pCREB-1, prominently decreased CREB-1 mRNA levels were observed in antifolate-resistant cells. We therefore explored the possibility that these cells were defective in CREB-1 phosphorylation, thereby resulting in down-regulation of some cAMP-responsive genes. Two-dimensional gel electrophoresis revealed that CREB-1 and its phosphoisoforms were markedly decreased in these cells. Treatment with forskolin, an activator of adenylyl cyclase, restored both CREB-1 and pCREB-1 levels; this resulted in restoration of CRE-binding, CRE-reporter activity, as well as CREB-1 and RFC mRNA levels. Hence, the protein kinase A (PKA) pathway was examined using various agents that augment intracellular cAMP levels including cholera toxin, an upstream agonist that renders stimulatory G-proteins (G{alpha}s) constitutively active. Treatment of antifolate-resistant cells with these agents resulted in restoration of pCREB-1 levels and CRE-reporter activity. Furthermore, transient transfection with a constitutively transcriptionally active VP16-CREB-1 that does not require phosphorylation for its activity resulted in restoration of CREB mRNA levels but not pCREB-1 levels. This is the first demonstration that resistance to various antifolates may potentially be associated with impaired activity of G{alpha}s or their coupled receptors resulting in loss of CREB-1 phosphorylation and consequent down-regulation of cAMP responsive genes.


Key words: Gs family, cAMP, CREB, DNA binding sites, Resistance





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics